Fishman, J.; Kuranz, S.; Yeh, M.M.; Brzozowski, K.; Chen, H.
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematol. Rep. 2023, 15, 266-282.
https://doi.org/10.3390/hematolrep15020027
AMA Style
Fishman J, Kuranz S, Yeh MM, Brzozowski K, Chen H.
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology Reports. 2023; 15(2):266-282.
https://doi.org/10.3390/hematolrep15020027
Chicago/Turabian Style
Fishman, Jesse, Seth Kuranz, Michael M. Yeh, Kaylen Brzozowski, and Herman Chen.
2023. "Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network" Hematology Reports 15, no. 2: 266-282.
https://doi.org/10.3390/hematolrep15020027
APA Style
Fishman, J., Kuranz, S., Yeh, M. M., Brzozowski, K., & Chen, H.
(2023). Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology Reports, 15(2), 266-282.
https://doi.org/10.3390/hematolrep15020027
